



Bronchodilator responsiveness and dyanapsis in bronchopulmonary dysplasia

Leif D. Nelin ^{1,2}, Matthew J. Kielt ¹, Maria Jebbia ¹, Sudarshan Jadcherla ² and Edward G. Shepherd ¹

¹Comprehensive Center for Bronchopulmonary Dysplasia, Nationwide Children's Hospital and Division of Neonatology, Dept of Pediatrics, The Ohio State University, Columbus, OH, USA. ²Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

Corresponding author: Leif D. Nelin (Leif.Nelin@nationwidechildrens.org)



Shareable abstract (@ERSpublications)

In 93 BPD patients, 63% were responsive to bronchodilators and responders had significantly lower FEV_{0.5} and greater hyperinflation than did non-responders. The dyanapsis ratio in responders was significantly smaller than in non-responders. <https://bit.ly/3yaWieK>

Cite this article as: Nelin LD, Kielt MJ, Jebbia M, et al. Bronchodilator responsiveness and dyanapsis in bronchopulmonary dysplasia. *ERJ Open Res* 2022; 8: 00682-2021 [DOI: 10.1183/23120541.00682-2021].

Copyright ©The authors 2022

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 3 Dec 2021
Accepted: 26 April 2022

Abstract

Background The incidence of bronchopulmonary dysplasia (BPD) following preterm birth is increasing. Bronchodilators are often used to treat patients with BPD with little evidence to guide therapy. The aim of this study was to test the hypothesis that there are infant pulmonary function test (iPFT) parameters that can predict subsequent bronchodilator response in infants with BPD.

Methods Subjects in this study were part of a patient group in which we reported three BPD phenotypes (obstructive, restrictive and mixed) based on iPFT data. From that group, a cohort of 93 patients with iPFT data including bronchodilator response was eligible for this study.

Results Bronchodilator responsiveness was found in 59 people (63%) in the cohort. There were no differences in demographics between the responders and non-responders. There was no difference in forced vital capacity (FVC) between the two groups. Responders had significantly lower forced expiratory volume in 0.5 s (FEV_{0.5}) and FEV_{0.5}/FVC ($p < 0.005$) and greater indices of hyperinflation than did non-responders ($p < 0.005$). Logistic regression modelling found that pre-bronchodilator FEV_{0.5} and functional residual capacity/total lung capacity were significantly associated with bronchodilator response. The magnitude of response to bronchodilators was negatively correlated ($R = -0.49$, $R^2 = 0.24$, $p < 0.001$) with the FEV_{0.5}. The median dyanapsis ratio in responders (0.08, 95% CI 0.05–0.19) was significantly ($p = 0.005$) smaller than in non-responders (0.18, 95% CI 0.06–0.38).

Conclusion These findings demonstrate that there are pulmonary function test parameters associated with bronchodilator response. Responders had evidence of greater dyanaptic lung growth than non-responders.

Introduction

Bronchopulmonary dysplasia (BPD) was first described by NORTHWAY *et al.* [1] in 1967 and is now the most common morbidity following preterm birth, with an incidence that is increasing [2, 3]. A recent definition of BPD based on respiratory support at 36 weeks post-menstrual age (PMA) divides BPD into three grades: Grade 1, low-flow nasal cannula; Grade 2, noninvasive positive pressure; and Grade 3, invasive positive pressure [4]. There is little high-grade evidence to support therapeutic approaches in patients with BPD, but despite this lack of evidence patients with BPD are often treated with bronchodilators [5, 6]. However, the use of bronchodilators in BPD is extremely variable between providers and between centres [7, 8].

Pulmonary function studies have been reported in children and young adult survivors of BPD [9–11] as well as in preterm infants developing BPD [12]. However, there is little pulmonary function data from infants with established BPD during their neonatal intensive care unit (NICU) hospitalisation. We recently described a cohort of patients with BPD who had infant pulmonary function testing (iPFT) done during their NICU hospitalisation and found that the iPFT data divided the patients into three phenotypes:



obstructive, restrictive and mixed [13]. We also reported [13] that in those infants tested for bronchodilator responsiveness (BDR), 66% had BDR and those with BDR had a lower pre-bronchodilator (pre-BD) forced expiratory volume in 0.5 s ($FEV_{0.5}$). This finding led us to hypothesise that iPFT parameters can be used to predict BDR in infants with established BPD during their NICU hospitalisation.

Modelling the airways as tubes and using Poiseuille's law suggests that airway diameter has the greatest effect on airway resistance and the smallest airways have the greatest resistance [14]. It has been shown even in young children and infants without lung disease that peripheral airways have high resistance, and that there is a marked decrease in resistance at 4–5 years of age [15]. Dysanaptic lung growth refers to the non-proportional growth of airways and lung resulting in relatively small airways for lung size [16]. It has been suggested that the dysanapsis ratio (DR) can be used as a noninvasive method of describing the relationship between airway calibre and lung size, where the smaller the DR, the greater the dysanaptic lung growth [17]. The DR has been shown in adults to be a predictor of expiratory flow limitation [18, 19]. To the best of our knowledge, no one has examined the DR in relation to BDR in infants with established BPD. Therefore, we tested the hypothesis in these infants with BPD and assessment of BDR, that those with BDR would have a smaller DR than non-responders. In other words, infants with BDR would have relatively smaller airways relative to their lung size than non-responsive infants.

Methods

This study was approved by the institutional review board at Nationwide Children's Hospital, Columbus, Ohio, USA, and informed parental consent was obtained from all subjects.

Subjects

The subjects in this cohort are the subset of a cohort that was described in our recent publication [13] who had BDR testing done. Briefly, data were collected from infants hospitalised in the NICU with a primary diagnosis of BPD who were referred for their first iPFT from May 1, 2003, to October 8, 2015. In our BPD unit, patients are referred for iPFT when they fail to make significant progress; the decision to refer for iPFT is made by consensus of the multidisciplinary BPD team. We estimate that the cohort represents ~15% of all BPD patients admitted to our BPD unit during this time frame.

iPFT

All iPFTs were performed using the Infant Pulmonary Laboratory (nSpire Health, Inc., Longmont, CO, USA). If present at the time of iPFT, endotracheal tubes or tracheostomy tubes were replaced with cuffed tubes prior to testing. Infants were sedated with chloral hydrate and underwent raised volume rapid thoracic compression spirometry and body plethysmography measurements as previously described [13, 20–22]. The reproducibility of these measurements in our iPFT laboratory has been previously reported, as have the normative data [20–22].

BDR testing

Albuterol was held for 8 h prior to testing. After pre-BD iPFTs were completed, two puffs of albuterol were given every 2 min until a 10% increase in heart rate was noted or a maximum of eight puffs were given, and then the iPFTs were repeated. For this study, we defined BDR as a >10% increase in $FEV_{0.5}$ (% predicted) as previously described by GOLDSTEIN *et al.* [21], which represents ≥ 2 SD above the normative mean for change in $FEV_{0.5}$ in infants. The coefficient of variation for $FEV_{0.5}$ is 2.2% [21].

DR

The DR is calculated from the forced expiratory flow at 50% (FEF_{50}) of forced vital capacity (FVC), using the equation $FEF_{50}/(FVC \times Pst(l)_{50})$ [19], where $Pst(l)_{50}$ is the static recoil pressure at 50% of FVC. We used data from TURNER *et al.* [23] to extrapolate $Pst(l)_{50}$ based on the equation $Pst(l)_{50} = -0.056 \times \text{age (years)} + 6.3038$, as previously described in both adults [18, 19] and children [24]. The DR is inversely related to dysanaptic lung growth, *i.e.* the smaller the DR, the more dysanapsis.

Data analysis

Pulmonary function data were collected in accordance with American Thoracic Society/European Respiratory Society guidelines [25], and for each subject represent three measurements within 5–10% of each other. iPFT data are given as % predicted. Data were also collected on subject demographics and outcomes.

Statistical analysis

Data are presented as median and interquartile range (IQR), mean \pm SD or number (%). The continuous data were compared between groups using a Mann–Whitney U test (Sigmaplot 14.0, Jandel Scientific,

Carlsbad, CA, USA). A Fisher's exact test was used to compare categorical data between groups (GraphPad Prism 8, GraphPad, San Diego, CA, USA). Selected variables were used in multiple logistic regression modelling (Sigmaplot) and results are presented as odds ratio and 95% confidence interval. The area under the receiver operating characteristic curve (AUROC) was calculated for selected variables (GraphPad). Linear regression modelling was used for some data pairs (Sigmaplot). A p-value of <0.05 was considered significant.

Results

There were 93 patients with BDR testing: 59 (63%) met criteria for BDR and were termed responders, and the remaining 34 (37%) were termed non-responders. There were no differences in any of the demographic variables between the two groups (table 1). Importantly, at the time of iPFT there were no differences between the two groups in terms of PMA, length, weight or type of respiratory support. The majority of infants (62%) had Grade 3 BPD, 24% had Grade 2 BPD and 2% had Grade 1 BPD. An additional nine infants (11%) lacked reliable respiratory support data at 36 weeks PMA and were therefore non-classifiable.

The pre-BD iPFT results are shown in table 2. There were 47 infants (51%) categorised as having obstructive BPD ($FEV_{0.5} < 80\%$ predicted and total lung capacity (TLC) $\geq 90\%$ predicted), 38 (41%) categorised as having mixed BPD (TLC $< 90\%$ predicted and $FEV_{0.5}/FVC < 90\%$ predicted) and eight (9%) categorised as having restrictive BPD (TLC $< 90\%$ predicted and $FEV_{0.5}/FVC \geq 90\%$ predicted). There were more infants with moderate/severe obstruction in the responder group than in the non-responder group. Responders had lower $FEV_{0.5}$ and $FEV_{0.5}/FVC$ than non-responders. Responders had greater indices of hyperinflation on iPFT (residual volume (RV)/TLC and functional residual capacity (FRC)/TLC) than non-responders.

TABLE 1 Demographics

	Responders	Non-responders	p-value
Subjects, n	59	34	
Gestational age (weeks)	25.7 (24.4–27.0)	25.3 (24.6–27.0)	0.90
Birth weight (g)	698 (585–883)	724 (589–920)	0.53
PMA at iPFT (weeks)	51 (45–57)	53 (47–70)	0.10
Post-partum age at iPFT (months)	5.8 (4.7–10.3)	5.8 (4.4–7.5)	0.17
Weight at iPFT (kg)	4.5 (3.7–5.4)	4.5 (3.7–6.7)	0.38
Growth velocity ($g \cdot day^{-1}$) [#]	10.5 (8.9–12.7)	9.3 (7.2–12.3)	0.07
Length at iPFT (cm)	53 (49–57)	54 (50–62)	0.27
Length z-score at iPFT [¶]	−2.11 (−3.05–−1.18)	−1.80 (−3.81–−1.00)	0.70
Respiratory support at iPFT			
Noninvasive	22 (37%)	17 (50%)	0.28
Endotracheal tube	20 (34%)	6 (18%)	0.15
Tracheostomy	17 (29%)	11 (32%)	0.82
Family history of asthma	23 (41%) [*]	8 (27%) ^f	0.24
Pregnancy tobacco exposure	20 (36%) ⁺	14 (42%) ^{##}	0.65
Antenatal steroids	48 (84%) [§]	27 (79%) ^{¶¶}	0.58
Race			
Black	15 (25%)	11 (32%)	0.48
White	41 (69%)	19 (56%)	0.26
Severe IVH	4 (7%)	4 (12%)	0.46
PDA ligation	23 (41%)	14 (41%)	1.0
NEC	5 (8%)	1 (3%)	0.41
Grade 3 BPD	39 (66%)	19 (56%)	0.38
Grade 2 BPD	14 (24%)	10 (29%)	0.63
Grade 1 BPD	1 (2%)	1 (3%)	1.0
Unknown at 36 weeks	5 (8%)	4 (12%)	0.72
RSS at 36 weeks	6.2 (4.1–8.9) ⁺⁺	7.5 (3.8–9.1) ^{§§}	0.59

Data shown as median (interquartile range) or n (%), unless otherwise indicated. PMA: post-menstrual age; iPFT: infant pulmonary function test; IVH: intraventricular haemorrhage; PDA: patent ductus arteriosus; NEC: necrotising enterocolitis; BPD: bronchopulmonary dysplasia; RSS: respiratory severity score. [#]: from birth to iPFT using the exponential calculation; [¶]: calculated from Centers for Disease Control and Prevention-National Center for Health Statistics length curves for 0–36 months of age; ^{*}: n=56; [§]: n=57; ^f: n=30; ^{##}: n=33; ^{¶¶}: n=34; ⁺⁺: n=49; ^{§§}: n=25.

TABLE 2 Pre-bronchodilator iPFT results

	Responders	Non-responders	p-value
Subjects, n	59	34	
Phenotype			
Obstructive	34 (58%)	13 (38%)	0.087
Restrictive	2 (3%)	6 (18%)	0.048
Mixed	23 (39%)	15 (44%)	0.67
Moderate/severe obstruction	53 (93%)	18 (64%)	0.002
Flows			
FVC (% predicted)	76 (61–90)	77 (66–102)	0.41
FEV _{0.5} (% predicted)	42±13	55±16	< 0.0001
FEV _{0.5} /FVC (% predicted)	57±18	70±20	< 0.005
FEF ₅₀ (% predicted)	13.2 (7.4–26.2)	28.4 (15.7–66.0)	< 0.001
FEF _{25–75} (% predicted)	11.5 (7.2–21.7)	24.7 (13.0–56.0)	< 0.001
Volumes			
FRC (% predicted)	112 (68–150)	97 (69–115)	0.14
RV (% predicted)	124 (72–171)	108 (76–125)	0.17
TLC (% predicted)	96 (82–120)	85 (73–121)	0.21
RV/TLC	54.5 (47.7–59.7)	47.7 (43.7–54.5)	0.002
FRC/TLC	65.1±7.4	57.0±9.5	< 0.0001
VC (mL)	97 (74–138)	118 (93–154)	0.035
Compliance			
C _{RS} (% predicted)	64 (47–99)	74 (64–95)	0.20
C _{RS} /kg	1.00 (0.87–1.21)	1.08 (0.92–1.49)	0.30

Data shown as median (interquartile range), mean±SD or n (%), unless otherwise indicated. Bold text signifies p<0.05. iPFT: infant pulmonary function test; FVC: forced vital capacity; FEV_{0.5}: forced expiratory volume in 0.5 s; FEF₅₀: forced expiratory flow at 50% of FVC; FEF_{25–75}: forced expiratory flow between 25% and 75% of FVC; FRC: functional residual capacity; RV: residual volume; TLC: total lung capacity; VC: vital capacity (TLC–RV); C_{RS}: compliance of the respiratory system.

The expiratory flow or indices of hyperinflation from the pre-BD iPFTs that were significantly different between responders and non-responders were used in multiple logistic regression models. To avoid over-fitting our models we examined flows (parameters=7) and indices of hyperinflation (parameters=6) separately, and included PMA, length and weight at the time of iPFT in the models. When pre-BD expiratory flows were used in the logistic regression model, only pre-BD FEV_{0.5} was significantly associated with BDR (table 3). When the indices of hyperinflation were used in the logistic regression model, only pre-BD FRC/TLC was associated with BDR (table 3). The AUROCs for pre-BD FEV_{0.5}, FEF₅₀ and FRC/TLC are given in table 4.

TABLE 3 Logistic regression parameters

	OR (95% CI)	p-value
FEV _{0.5}	0.93 (0.88–0.99)	0.022
FEV _{0.5} /FVC	1.01 (0.97–1.07)	0.53
FEF ₅₀	0.93 (0.82–1.07)	0.30
FEF _{25–75}	1.06 (0.92–1.22)	0.41
RV/TLC	0.97 (0.90–1.05)	0.47
FRC/TLC	1.19 (1.07–1.33)	0.001
VC	0.99 (0.98–1.01)	0.46
DR [#]	0.011 (0.001–0.195)	0.002

Bold text signifies p<0.05. FEV_{0.5}: forced expiratory volume in 0.5 s; FVC: forced vital capacity; FEF₅₀: forced expiratory flow at 50% of FVC; FEF_{25–75}: forced expiratory flow between 25% and 75% of FVC; RV: residual volume; TLC: total lung capacity; FRC: functional residual capacity; VC: vital capacity (TLC–RV); DR: dysanapsis ratio. [#]: values for DR have a relatively narrow range (0.013–0.856).

TABLE 4 AUROCs

	AUROC	95% CI
Pre-BD FEV _{0.5}	0.73	0.62–0.84
FRC/TLC	0.74	0.64–0.84
DR	0.68	0.56–0.79

AUROC: area under the receiver operating characteristics curve; pre-BD: pre-bronchodilator; FEV_{0.5}: forced expiratory volume in 0.5 s; FRC: functional residual capacity; TLC: total lung capacity; DR: dysanapsis ratio.

To determine if the magnitude of BDR in responders was related to pre-BD flows, hyperinflation or both, we examined the magnitude of BDR as given by the change in FEV_{0.5} pre-BD to post-BD in responders. The median magnitude of BDR in the 59 responder patients was 26% (IQR 19–39%). The magnitude of BDR in the responders was negatively correlated with the pre-BD FEV_{0.5} (figure 1). The magnitude of BDR in responders was not correlated with the pre-BD FRC/TLC ($R=0.21$, $R^2=0.04$, $p=0.11$).

The median DR in responders was significantly smaller than the median DR in non-responders (figure 2a), suggesting greater dysanaptic lung growth in responders than non-responders. Because we were using an algorithm for calculating Pst(l)₅₀ that used age in years, and given that our range of ages in years was quite narrow (0.23–1.91 years), we examined the relationship between DR and chronological age in years for the entire cohort and found no significant correlation by linear regression ($R=0.11$, $R^2=0.01$, $p=0.31$). There was also no correlation between DR and PMA (in weeks) ($R=0.12$, $R^2=0.01$, $p=0.27$). Examining the relationship between DR and FEV_{0.5} using linear regression we found a significant correlation (figure 2b). We also examined the relationship of DR to TLC using linear regression and found a significant negative correlation (figure 2c). Using multiple logistic regression modelling and including PMA and length and weight at time of iPFT, DR predicted BDR with OR 0.011 (95% CI 0.001–0.195, $p=0.002$; table 3).

There were no differences in outcomes between the two groups (table 5).

Discussion

This study demonstrates that in a cohort of NICU patients with BPD referred for iPFT, the majority of which had Grade 3 BPD, 63% of patients were responsive to bronchodilators. There were no demographic differences between responders and non-responders in this cohort of infants. We did find that pre-BD




FIGURE 1 The magnitude of bronchodilator responsiveness (BDR) is negatively correlated with forced expiratory volume in 0.5 s (FEV_{0.5}). The linear regression fit (solid line) ($y=-0.72x+62$, $R=-0.49$, $R^2=0.24$, $p<0.001$) suggests that 24% of the variation in the magnitude of BDR is due to FEV_{0.5}. The dashed line represents the threshold for BDR.




FIGURE 2 a) Dysanapsis ratio (DR) was significantly larger in non-responders than in responders. b) DR was correlated with the forced expiratory volume in 0.5 s ($FEV_{0.5}$) (linear regression fit; $y=0.007x-0.174$, $R=0.62$, $R^2=0.39$, $p<0.001$). c) DR is negatively correlated with total lung capacity (TLC) ($y=-0.003x+0.434$, $R=-0.44$, $R^2=0.19$, $p<0.001$).

values for $FEV_{0.5}$ and FEF_{50} were lower in responders than in non-responders, with more hyperinflation as assessed by RV/TLC and FRC/TLC on the iPFT in responders than in non-responders. Indeed, the $FEV_{0.5}$ and FRC/TLC were modestly predictive of BDR in this cohort using logistic regression modelling and AUROC analysis.

Infants in this cohort all had BPD and all but two subjects had either Grade 2 or Grade 3 BPD. Even in this population in which 91% had obstruction, 37% of the subjects were non-responsive to bronchodilators. The cohort is not a consecutive cohort of all patients with Grade 2 or Grade 3 BPD, but rather infants chosen for iPFT based on no clinical response to usual therapy. Several studies have examined BDR in older children or young adults who have BPD [9, 10, 11], but there are very few published studies examining BDR using iPFT in BPD infants during their initial NICU hospitalisation. MORROW *et al.* [26] evaluated 40 preterm infants with evolving BPD with iPFTs at a mean PMA of 35 weeks and found that 65% had a response to bronchodilators, and responders tended to have a greater baseline respiratory system resistance than non-responders [26], consistent with our findings that responders tended to have a lower $FEV_{0.5}$ than non-responders. ROBIN *et al.* [27] evaluated 17 infants with BPD at a mean postnatal age of 68 weeks (our cohort had a mean postnatal age of 30 weeks) and found that 35% had significant BDR (defined as a change in $FEF_{75} >24.3\%$). Furthermore, they reported that responders had significantly lower baseline FEF_{75} than non-responders [27], again consistent with our findings. Together with our data, these findings support the notion that not all patients with established BPD have BDR and that patients with greater obstruction at baseline are more likely to demonstrate BDR.

Responders had more hyperinflation on iPFT than non-responders, as evidenced by larger RV/TLC and FRC/TLC ratios as well as smaller vital capacity. It has been shown that infants with BPD have greater RV/TLC than infants without BPD [27]. Recently, YODER *et al.* [28] used magnetic resonance imaging (MRI) to measure FRC in NICU patients at PMA between 35 and 42 weeks and found that subjects with

TABLE 5 Outcomes

	Responders	Non-responders	p-value
Subjects, n	59	34	
Survived	54 (92%)	33 (97%)	0.41
Total ventilator days	168 (102–312)	141 (85–257)	0.36
Total ventilator days survivors	163 (99–268)	141 (83–237)	0.59
Ventilator days after iPFT	56 (22–146)	72 (32–261)	0.62
Length of stay (days)	316 (217–468)	294 (208–479)	0.58
Length of stay after iPFT (days)	139 (73–287)	97 (55–195)	0.13
Tracheostomy after iPFT	4 (7%)	1 (3%)	0.65
Discharge on IMV	6 (10%)	2 (6%)	0.71

Data shown as median (interquartile range) or n (%), unless otherwise indicated. iPFT: infant pulmonary function testing; IMV: invasive mechanical ventilation.

severe BPD had significantly greater FRC than subjects with mild BPD. DASSIOS *et al.* [29] found that the greater the degree of hyperinflation in preterm infants (studied at a median of 6 weeks of age), the greater the ventilation/perfusion mismatch. To the best of our knowledge we are the first to describe in a cohort of patients with BPD that there are measurable differences in hyperinflation, with more hyperinflation in those infants who respond to bronchodilators than in those who do not respond. In adults with chronic obstructive pulmonary disease, it has also been reported that patients with lung hyperinflation have better bronchodilator responsiveness [30]. These findings suggest that the degree of hyperinflation may underlie BDR in BPD and further studies are needed to examine biomarkers of hyperinflation in relation to BDR. These findings also raise the question of whether bronchoconstriction is involved in the mechanism underlying hyperinflation in BPD.

We found no evidence of a pre-BD FEV_{0.5} cut-off value for predicting BDR, but there was a negative correlation between the magnitude of BDR and FEV_{0.5}. The lung volume parameters FRC/TLC and RV/TLC were not significantly correlated with the magnitude of BDR. These findings have potential implications for precision therapeutics in BPD. Multicentre studies have shown extreme variability in bronchodilator use in patients with severe BPD [5–8], which suggests a lack of high-quality evidence to support the precise utilisation of bronchodilators targeting those patients who may benefit from the medication. In our unit, these patients are treated with bronchodilators. Our findings demonstrate that not all infants with severe BPD demonstrate BDR, which may lead clinicians to use other criteria (*e.g.* physical examination, changes in delivered tidal volumes or pressures on the ventilator, tolerance of therapies) that are not standardised to guide their use of bronchodilators. Our findings also suggest that iPFT data can predict BDR in the most severe forms of BPD. It should be remembered that though bronchodilators are widely used and generally considered safe in BPD patients, bronchodilators are not without risk [31, 32]. Targeting the use of bronchodilators to BPD patients with physiological evidence of expiratory flow limitation on iPFT may be one way to optimise therapeutic effects while avoiding medication side-effects.

The mechanisms underlying bronchoconstriction and BDR in patients with BPD are likely to be very complex and multifactorial; understanding exactly the mechanisms involved in this cohort are beyond the scope of this study or any single study. However, we did wonder how lung growth and, particularly, dysanaptic lung growth might affect BDR in established BPD in patients still in the NICU. We found in this cohort of BPD patients that the DR was smaller in responders than in non-responders, suggesting that BPD patients with BDR likely have relatively smaller airways in proportion to their lung size than non-responders. DUKE *et al.* [19] reported in adult survivors of preterm birth that those with BPD had smaller DR than adult survivors of preterm birth without BPD, and that the DR was significantly correlated with peak expiratory airflow at rest and the extent of expiratory flow limitation during exercise. This suggests that at least some of the BD response in the responder group may be due to their relatively smaller airways in relation to lung size. Another way to think of this is that in patients with lower DR, the relatively smaller airways in relation to lung size would be more likely to have a measurable change in iPFT parameters following BD administration. Furthermore, patients with smaller DR would be expected to have lower FEV_{0.5} and FEF₅₀ due to the relatively higher airway resistance, and we found a direct correlation between DR and FEV_{0.5} in this cohort. The relationship between DR and FEV_{0.5} also suggests that dysanaptic airway development underlies at least some of the BDR seen in the responder group in this cohort of NICU patients with BPD. The finding that DR was correlated with TLC and that the patients with the largest TLC (*i.e.* the greatest amount of hyperinflation) had the lowest DR may suggest that dysanaptic lung growth also contributes to the hyperinflation seen in patients with severe BPD. Further studies are needed that examine dysanaptic lung growth in BPD. It would be interesting to examine, for instance, whether DR increases with good somatic growth, *i.e.* if airway calibre increases relatively more than lung size increases as the lung grows, and whether this is a mechanism for the improvement in lung function seen in established BPD with good linear growth.

There are some limitations to this study that should be noted. First, it was not a consecutive cohort of subjects, and thus not a true epidemiological assessment of BDR in BPD. However, as far as we know this is the largest cohort of BPD infants with BDR testing during the initial NICU hospitalisation. Another aspect of this is that the patients studied represent the severest forms of BPD given that the patients were referred if they were not responding as expected. Thus, these data may not be widely generalisable to all BPD. Second, to obtain the measurement of DR we used static recoil pressures at 50% of lung volume (Pst(l)₅₀) extrapolated from adult values [23] as has been previously described [18, 19, 24]. However, given the lung growth that occurs from birth through early childhood, the assumption of a linear relationship of Pst(l)₅₀ values with age in early childhood may not be entirely valid [15]. However, despite this limitation we were able to find differences in DR between infants, expected correlations with other iPFT parameters, and no significant correlation between DR and age in this cohort. A third potential

limitation might be that we were unable to correlate our iPFT findings with either thorough physical examination data or rigorous imaging data. Another potential limitation is that iPFT is not widely available in this age range of patients. However, with advances in ventilator technology, ventilators now provide in-line measurements of at least some aspects of pulmonary function and there continues to be the development of new methods of measuring pulmonary function in this age group (such as forced oscillometry, MRI, *etc.*). Finally, the parameters studied here to predict BDR were only moderately predictive using AUROC analysis; thus, further studies to find better predictive tests for BDR are required, and these predictive lung function tests should include parameters readily available to the clinician.

Conclusion

We found in a cohort of patients with BPD that most, but not all, were responsive to bronchodilators. The measured iPFT parameters associated with BDR in this cohort were FEV_{0.5} and FRC/TLC ratio. Our results suggest that future studies are needed to better predict BDR in patients with BPD. Interestingly, the group of responders demonstrated dysanaptic lung growth, suggesting relatively small airways compared to their lung size. A better understanding of how airways and lung parenchyma grow in BPD patients may shed light on disease progression.

Provenance: Submitted article, peer reviewed.

Conflict of interest: The authors have no conflicts of interest relevant to this article to disclose.

References

- 1 Northway WH, Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease—bronchopulmonary dysplasia. *N Engl J Med* 1967; 276: 357–368.
- 2 Abman SH, Collaco JM, Shepherd EG, *et al.* Interdisciplinary care of children with severe bronchopulmonary dysplasia. *J Pediatr* 2017; 181: 12–28.
- 3 Stoll BJ, Hansen NI, Bell EF, *et al.* Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. *JAMA* 2015; 314: 1039–1051.
- 4 Jensen EA, Dysart K, Gantz MG, *et al.* The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. *Am J Respir Crit Care Med* 2019; 200: 751–759.
- 5 Kiehl MJ, Logan JW, Backes CH, *et al.* In-hospital outcomes of late referrals for established bronchopulmonary dysplasia. *J Perinatol* 2021; 41: 1972–1982.
- 6 Bamat NA, Kirpalani H, Feudtner C, *et al.* Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals. *J Perinatol* 2019; 39: 1291–1299.
- 7 Slaughter JL, Stenger MR, Reagan PB, *et al.* Inhaled bronchodilator use for infants with bronchopulmonary dysplasia. *J Perinatol* 2015; 35: 61–66.
- 8 Guaman MC, Gien J, Baker CD, *et al.* Point prevalence, clinical characteristics, and treatment variation for infants with severe bronchopulmonary dysplasia. *Am J Perinatol* 2015; 32: 960–967.
- 9 Doyle LW, Carse E, Adams AM, *et al.* Ventilation in extremely preterm infants and respiratory function at 8 years. *N Engl J Med* 2017; 377: 329–337.
- 10 Um-Bergström P, Hallberg J, Pourbazargan M, *et al.* Pulmonary outcomes in adults with a history of bronchopulmonary dysplasia differ from patients with asthma. *Respir Res* 2019; 20: 102.
- 11 Bhandari A, McGrath-Morrow S. Long-term pulmonary outcomes of patients with bronchopulmonary dysplasia. *Semin Perinatol* 2013; 37: 132–137.
- 12 Chen IL, Chen HL. Lung function and relevant clinical factors in very low birth weight preterm infants with chronic lung disease: an observational study. *Can Respir J* 2019; 2019: 5824180.
- 13 Shepherd EG, Clouse BJ, Hasenstab KA, *et al.* Infant pulmonary function testing and phenotypes in severe bronchopulmonary dysplasia. *Pediatrics* 2018; 141: e20173350.
- 14 Hogg JC, Paré PD, Hackett TL. The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. *Physiol Rev* 2017; 97: 529–552.
- 15 Hogg JC, Williams J, Richardson JB, *et al.* Age as a factor in the distribution of lower-airway conductance and in the pathologic anatomy of obstructive lung disease. *N Engl J Med* 1970; 282: 1283–1287.
- 16 Llapur CJ, Martínez MR, Grassino PT, *et al.* Chronic hypoxia accentuates dysanaptic lung growth. *Am J Respir Crit Care Med* 2016; 194: 327–332.
- 17 Mead J. Dysanapsis in normal lungs assessed by the relationship between maximal flow, static recoil, and vital capacity. *Am Rev Respir Dis* 1980; 121: 339–342.
- 18 Smith JR, Rosenkranz SK, Harms CA. Dysanapsis ratio as a predictor for expiratory flow limitation. *Respir Physiol Neurobiol* 2014; 198: 25–31.
- 19 Duke JW, Gladstone IM, Sheel AW, *et al.* Premature birth affects the degree of airway dysanapsis and mechanical ventilatory constraints. *Exp Physiol* 2018; 103: 261–275.

- 20 Castile R, Filbrun D, Flucke R, *et al.* Adult-type pulmonary function tests in infants without respiratory disease. *Pediatr Pulmonol* 2000; 30: 215–227.
- 21 Goldstein AB, Castile RG, Davis SD, *et al.* Bronchodilator responsiveness in normal infants and young children. *Am J Respir Crit Care Med* 2001; 164: 447–454.
- 22 Tepper RS, Williams T, Kisling J, *et al.* Static compliance of the respiratory system in healthy infants. *Am J Respir Crit Care Med* 2001; 163: 91–94.
- 23 Turner JM, Mead J, Wohl ME. Elasticity of human lungs in relation to age. *J Appl Physiol* 1968; 25: 664–671.
- 24 Pianosi PT. Flow limitation and dysanapsis in children and adolescents with exertional dyspnea. *Respir Physiol Neurobiol* 2018; 252–253: 58–63.
- 25 American Thoracic Society, European Respiratory Society. ATS/ERS statement: raised volume forced expirations in infants: guidelines for current practice. *Am J Respir Crit Care Med* 2005; 172: 1463–1471.
- 26 Morrow DK, Schilling D, McEvoy CT. Response to bronchodilators in very preterm infants with evolving bronchopulmonary dysplasia. *Res Rep Neonatol* 2015; 5: 113–117.
- 27 Robin B, Kim YJ, Huth J, *et al.* Pulmonary function in bronchopulmonary dysplasia. *Pediatr Pulmonol* 2004; 37: 236–242.
- 28 Yoder LM, Higano NS, Schapiro AH, *et al.* Elevated lung volumes in neonates with bronchopulmonary dysplasia measured via MRI. *Pediatr Pulmonol* 2019; 54: 1311–1318.
- 29 Dassios T, Curley A, Krokidis M, *et al.* Correlation of radiographic thoracic area and oxygenation impairment in bronchopulmonary dysplasia. *Respir Physiol Neurobiol* 2016; 220: 40–45.
- 30 Chen C, Jian W, Gao Y, *et al.* Early COPD patients with lung hyperinflation associated with poorer lung function but better bronchodilator responsiveness. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 2519–2526.
- 31 Panitch HB, Keklikian EN, Motley RA, *et al.* Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. *Pediatr Pulmonol* 1990; 9: 170–176.
- 32 Hysinger EB, Friedman NL, Padula MA, *et al.* Tracheobronchomalacia is associated with increased morbidity in bronchopulmonary dysplasia. *Ann Am Thorac Soc* 2017; 14: 1428–1435.